Atossa's Rare Pediatric Disease Designation for (Z)-endoxifen in neuromuscular diseases qualifies for a future PRV upon FDA approval About Rare Pediatric Disease Designation The FDA's Rare Pediatric Disease designation is reserved for serious or life-threatening diseases that primarily affect individuals from birth to 18 years old and that meet the definition of a rare disease or condition within the meaning of Section 526 of the Federal Food, Drug & Cosmetic Act ("FD&C Act"). Drugs granted RPD designation ...

The Seattle-based real estate company said the cuts — which represent about 2% of Zillow's overall headcount — were part of the annual review process. ...

2026 is kicking off on a rocky note in the stock markets, and amid rising macroeconomic uncertainties and geopolitical tensions, it's clear that investors are trying to dive into safety. With that in mind, I'm being especially selectiveWith combined experience of covering technology companies on Wall Street and working in Silicon Valley, and serving as an outside adviser to several seed-round startups, Gary Alexander has exposure to many of the themes shaping the industry today. He has been a regular contri ...

I focus on producing objective, data-driven research, mostly about small- to mid-cap companies, as these tend to be overlooked by many investors. From time to time, though, I also look at large-cap names, just to give a fuller sense of the broader equity markets.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in ...

Group 1 - The focus is on producing objective, data-driven research primarily about small- to mid-cap companies, which are often overlooked by many investors [1] - Occasionally, large-cap companies are analyzed to provide a broader perspective on the equity markets [1] Group 2 - No stock, option, or similar derivative positions are held in any of the companies mentioned, but there may be plans to initiate a beneficial long position in the near future [2] - The article expresses personal opinions and is not influenced by compensation from any company mentioned [2]

Core Insights - Atossa Therapeutics has received Orphan Drug Designation from the FDA for (Z)-endoxifen to treat Duchenne muscular dystrophy (DMD), which is a significant milestone for the company in its development efforts for this serious disease [1][2] Group 1: Company Overview - Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies in oncology and other areas with high unmet medical needs [7] - The company's lead product candidate, (Z)-endoxifen, is being evaluated for its potential applications in oncology and rare diseases [5][7] - Atossa has a growing global intellectual property portfolio supporting the (Z)-endoxifen program, including multiple recently issued U.S. patents and numerous pending applications worldwide [6] Group 2: Product Information - (Z)-endoxifen is a potent Selective Estrogen Receptor Modulator/Degrader (SERM/SERD) with demonstrated activity across multiple mechanisms of interest, showing a favorable safety profile distinct from tamoxifen [5] - The drug is not yet approved for any indication, and the company plans to continue engaging with the FDA as it advances its development efforts [2][5] Group 3: Disease Context - Duchenne Muscular Dystrophy (DMD) is a rare, progressive, X-linked neuromuscular disorder caused by mutations in the dystrophin gene, leading to severe symptoms and a substantial unmet medical need for effective treatments [4]

We came across a bearish thesis on Zillow Group, Inc. on investing subreddit by Guy_PCS. In this article, we will summarize the bears’ thesis on ZG. Zillow Group, Inc.'s share was trading at $67.80 as of January 13th. ZG’s forward P/E was 32.89 according to Yahoo Finance. Studio Grand Ouest/Shutterstock.com Zillow Group, Inc. operates real estate brands in mobile applications and Websites in the United States. ZG faced renewed investor concern after its stock declined more than 5.5% following reports th ...

Zillow (NASDAQ: Z and ZG) is recognized as one of the go-to platforms for homebuyers searching for properties, yet the bulk of its revenue stems from real estate listing agents who pay for leads. Under CEO Jeremy Wacksman, the company is increasingly shifting focus toward the transaction side of the real estate process, viewing it as a more promising avenue for growth. As Wacksman has noted, “It’s a better business to be in,” highlighting the potential for deeper involvement beyond mere lead generation.Cent ...

Core Insights - Atossa Therapeutics has received a "Study May Proceed" letter from the FDA for its clinical study of (Z)-endoxifen in metastatic breast cancer, marking a significant regulatory milestone for the company [1][2] Group 1: Product Development - (Z)-endoxifen is a potent Selective Estrogen Receptor Modulator/Degrader (SERM/D) with demonstrated activity across multiple mechanisms, currently under evaluation for oncology and rare diseases [3] - The proprietary oral formulation of (Z)-endoxifen has shown a favorable safety profile and distinct pharmacology compared to tamoxifen, including ER-targeted effects and PKC inhibition [3] - The (Z)-endoxifen program is supported by a growing global intellectual property portfolio, including multiple recently issued U.S. patents and numerous pending applications worldwide [4] Group 2: Company Overview - Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative medicines in oncology and other areas of significant unmet medical need [5] - The company's lead product candidate, (Z)-endoxifen, is currently in development across several clinical settings [5]

Core Insights - The US real estate market is experiencing seasonal cooling after an unusually active fall, with price cuts from sellers returning to normal levels [1] - Affordability remains a challenge for home buyers, but improvements in mortgage payments and rising incomes are providing some relief [3] Market Trends - Mortgage payments decreased by over $100 a month, contributing to improved affordability for many households [1] - New listings from sellers fell nearly 30% month over month in November, marking the largest decline since at least 2018 [1] - Price cuts from sellers decreased from 26.9% of listings in October to 21.2% in November, aligning with seasonal norms [1] Inventory and Sales - Newly pending sales fell 18.5% month over month in November, although they remained 3% above the previous year [1] - Inventory levels increased as sellers outnumbered buyers during the spring and early summer, with a peak growth of 22.8% in March [1][2] Home Values - Typical home values nationwide increased by only 0.2% over the past year, with 53% of home values falling during the same period [2] - The majority of homes have gained value since their last sale, indicating a mixed performance in the market [2] Affordability Metrics - Monthly mortgage payments for a typical house represented 35.7% of median household income at the start of the year, declining to 32.6% in November, the lowest since August 2022 [3] - Zillow economists anticipate a continued decline in mortgage rates into 2026, which may support a rebound in home values and sales [3]